About

A Clinical and Medical Affairs team for medical device companies.

Regenesis Scientific Strategy is a team of consultants from junior to senior level, led by a Principal Consultant, with exclusive partners in biostatistics, reimbursement and market access, and regulatory. We keep the literature current and review study data while the trial is still running. Scientific ownership stays with Regenesis Scientific Strategy. Engagements run from first evidence plan through commercial launch. The office is in Southlake, Texas, near Dallas–Fort Worth International Airport.

A quiet scientific study with journals, oak desk, and north light.

Team

A Principal Consultant is accountable for the engagement. Consultants do the work.

Consultants from junior to senior level staff the engagement. A Principal Consultant sets the plan, manages the engagement, and is accountable for delivery.

Founding Principal Consultant

Stephanie Washburn, PhD

Stephanie Washburn has nearly twenty years in medical device Clinical and Medical Affairs across Class I through III programs. She works as Principal Consultant and leads the team.

At Abbott (formerly St. Jude Medical Neuromodulation) she worked on spinal cord and peripheral nerve stimulation: post-market studies, IDE and post-approval work, 510(k) and CE support, and peer-reviewed papers in Neuromodulation, Cephalalgia, and the Clinical Journal of Pain. Roles included clinical monitoring, data analysis, project management, and medical writing.

As VP, Clinical and Medical Affairs at Spark Biomedical, she built the clinical function and managed the in-house study for opioid withdrawal, from Pre-Sub through FDA clearance.

She was an MSL for electroCore / gammaCore, supporting nVNS for migraine and cluster headache — field medical work for a commercial neuromodulation therapy, including scientific exchange with treating clinicians.

She was Head of Clinical and Medical Affairs Strategy at an early-stage SaMD start-up, building the clinical and evidence infrastructure the company needed before it had a Clinical and Medical Affairs department.

Path

From first evidence plan through commercial launch.

  1. Abbott

    SCS and PNS

    Clinical strategy and Medical Affairs at Abbott (formerly St. Jude Medical Neuromodulation) for spinal-cord and peripheral-nerve stimulation. Post-market studies, IDE and post-approval work, 510(k) and CE support, and peer-reviewed papers in Neuromodulation, Cephalalgia, and the Clinical Journal of Pain.

  2. electroCore / Spark

    Field and clinical leadership

    MSL for gammaCore (nVNS for migraine and cluster headache) — field medical work for a commercial neuromodulation therapy, including scientific discussions with treating clinicians. Then VP, Clinical and Medical Affairs at Spark Biomedical: a neurostimulation program for opioid withdrawal, taken from Pre-Sub through FDA clearance, with the clinical department built while the trial was executed.

  3. Early-stage SaMD start-up

    Clinical infrastructure

    Head of Clinical and Medical Affairs Strategy at an early-stage SaMD start-up — building the clinical and evidence infrastructure the company needed before it had a Clinical and Medical Affairs department.

  4. Today

    Regenesis Scientific Strategy

    Founding Principal Consultant at Regenesis Scientific Strategy, leading a team of consultants for medical device companies that need Clinical and Medical Affairs before they create a department. Women-owned.

Studies

Clinical studies.

A selection of studies Stephanie Washburn has worked on. Roles included clinical monitoring, data analysis, project management, and medical writing. Company names are the sponsors of those studies. Publications on PubMed.

Abbott (formerly St. Jude Medical)

  • Eon IPG post-market study. Clinical monitoring, data analysis, and writing. Abstracts, a clinical study report, and a Neuromodulation paper on pain catastrophizing and spinal cord stimulation.
  • Genesis IPG post-market study. Data analysis and writing. A clinical study report and a Clinical Journal of Pain meta-analysis.
  • Epiducer lead delivery system. Project management, clinical operations, data analysis, and writing. FDA approval, abstracts, a clinical study report, and two Neuromodulation papers.
  • Constant current versus constant voltage. Data analysis and writing. Abstracts and a Neuromodulation paper.
  • PAIN registry. Project management, data analysis, and writing. Abstracts and two Neuromodulation papers, including 24-month follow-up.
  • Occipital nerve stimulation for chronic migraine. Data analysis and writing. A randomized, multicenter, sham-controlled trial published in Cephalalgia, and an adverse-event analysis in Neuromodulation.
  • Peripheral nerve field stimulation feasibility. Medical writing and review. A clinical study report and a Neuromodulation paper.
  • SUNBURST. Research scientist. Abstracts and two papers, including the burst-waveform results in Neuromodulation.
  • ACCURATE IDE post-approval study. Project management.
  • Spinal cord stimulation for traumatic brain injury, feasibility. Data analysis, medical writing, and a clinical study report.

ImThera Medical

  • THN-3, hypoglossal nerve stimulation for sleep apnea. Director of Clinical Affairs.

Spark Biomedical

  • Transcutaneous nerve stimulation for opioid withdrawal. Project management, clinical operations, monitoring, and the Clinical Investigational Plan. The program went from Pre-Sub through FDA clearance.

Later sponsor work

  • Alpha-Tec EVOLVE. Data management, analysis, statistical analysis plan, clinical study report, and FDA approval.
  • Nalu. Scientific input on a spinal cord stimulation trial design, plus a registry Clinical Investigational Plan and data collection forms.
  • Presidio. Medical writing on a low-frequency spinal cord stimulation study. Clinical study report in process.
  • NeuraLace, CereGate, NeuroStasis, ReStalsis, and FemPulse. Clinical Investigational Plans and, where the study required them, case report forms, consent forms, and study documents.
  • Inogen, Philips IGTD, Quest Medical, and BlueWind Medical. Clinical evaluation process and clinical evaluation reports.
  • Medtronic. Subject-matter review and a draft history of spinal cord stimulation.
  • Neuronoff, PatchD, and Thermaquil. Clinical Investigational Plan, evidence-plan input, or standard operating procedures.

Partnerships

Exclusive partners, when the work needs them.

Clinical and Medical Affairs stays with Regenesis Scientific Strategy. Biostatistics, reimbursement and market access, and regulatory come in through exclusive partners.

Poplar Access Advisors

Reimbursement and market access

Poplar Access Advisors

Reimbursement and market access strategy for medical devices. Coding, coverage, payment, and payer evidence considered before first enrollment.

Poplar Access Advisors

02

Biostatistics

Biostatistics

Sample size, statistical analysis plans, adaptive design, and interim analysis. Regenesis Scientific Strategy leads trial data analytics and insights on live studies.

03

Regulatory

Regulatory

Regulatory strategy and submission support through exclusive partners, working with the company's regulatory representative.

Vision

One vendor for medical device development.

Today we provide Clinical and Medical Affairs strategy, preclinical development, fundraising strategy, and strategic and fractional leadership. When a program also needs biostatistics, reimbursement and market access, or regulatory work, we bring in exclusive partners.

The vision is that a medical device company can hire Regenesis Scientific Strategy for the whole development path — not a separate vendor for every function. You work with us. We coordinate the rest.

  • RSS leads
  • Exclusive partner
  • On the pathway

Concurrent work

Workstreams run at the same time. Planning keeps them aligned.

The columns are development phases, not a sequence you finish one at a time. R&D, preclinical, clinical, regulatory, marketing, and access run together and depend on each other. Clinical Evidence Strategy Planning (CESP) runs across all of them — including HCP input we identify and manage — so those workstreams stay aligned.

Do not hand a trial off and step away. The company still needs experienced trial management of its own — someone who knows the regulations and represents the sponsor. That is how a study stays on track and on budget. We work on the sponsor side. Small studies we can run. Larger studies we run with an execution partner.

CESP

Clinical Evidence Strategy Planning

A process, not a stage. It runs at the same time as R&D, preclinical, and clinical work.

  • Intended use and TPP
  • Evidence generation sequence
  • HCP input — identified and managed by RSS
  • Statistical strategy
  • Pre-Sub / Q-Sub
  • Protocol / CIP architecture
  • PMCF plan

Strategic and fractional leadership

Concept
  • Executive advisory, org development
Design
  • Program management
Preclinical
  • Program management
Feasibility
  • Program management
Pivotal
  • Program management
Submission
  • Program management
After
  • Executive advisory, org development

R&D

Concept
  • Concept development
Design
  • Prototype, design controls, QMS
Preclinical
  • Design iteration
Feasibility
  • Design freeze
Pivotal
  • Design lock
Submission
  • Design history
After
  • Product iteration

Preclinical development

Concept
  • Preclinical strategy
Design
  • Preclinical strategy
Preclinical
  • Bench, animal, GLP

Fundraising strategy

Concept
  • Grant writing
Preclinical
  • Non-dilutive study support
Feasibility
  • Non-dilutive study support
Pivotal
  • Non-dilutive study support

Regulatory strategy

Concept
  • Classification and pathway
Design
  • Design-control alignment
Preclinical
  • Test plan vs. FDA
Feasibility
  • IDE strategy — FIH / EFS / pilot
Pivotal
  • IDE strategy — pivotal
Submission
  • Submission strategy
After
  • Post-market regulatory strategy

Regulatory execution

Feasibility
  • IDE filing
Pivotal
  • IDE maintenance
Submission
  • 510(k), De Novo, PMA, CE
After
  • Supplements

Clinical Affairs

Concept
  • Clinical and Medical Affairs strategy
  • Site identification strategy
  • Investigator-initiated trials
Design
  • Site identification strategy
  • Investigator-initiated trials
Preclinical
  • Investigator-initiated trials
Feasibility
  • Sponsor-side trial management
  • FIH, EFS, feasibility, pilot
  • Site identification strategy
  • Small-scale study execution
  • Larger study — execution partner
  • Investigator-initiated trials
Pivotal
  • Sponsor-side trial management
  • Pivotal / confirmatory trial
  • Site identification strategy
  • Larger study — execution partner
  • Investigator-initiated trials
Submission
  • Clinical sections of the filing
  • Investigator-initiated trials
After
  • Sponsor-side trial management
  • Investigator-initiated trials
  • CEP / CER, PMCF

Medical Affairs

Concept
  • HCP input to CESP
  • Early KOL map
Feasibility
  • Investigator and KOL engagement
Pivotal
  • Investigator and KOL engagement
Submission
  • Medical review of claims
After
  • Fractional Medical Affairs

Scientific communications

Feasibility
  • Abstracts and posters
Pivotal
  • Abstracts and posters
After
  • Publications, congress, medical writing

Biostatistics strategy

Concept
  • Statistical strategy in the CESP
Design
  • Statistical strategy
Preclinical
  • Preclinical statistical strategy
Feasibility
  • Statistical strategy for FIH / pilot
Pivotal
  • Statistical strategy for pivotal
After
  • PMCF statistical strategy

Biostatistics execution

Feasibility
  • Sample size, SAP — before the trial
Pivotal
  • SAP, interim analysis — during the trial
Submission
  • Filing analyses — after the trial
After
  • Post-market analyses

Reimbursement / market access strategy

Concept
  • Payer evidence in the CESP
Feasibility
  • Endpoints payers will require
Pivotal
  • Endpoints payers will require
Submission
  • Access strategy for the filing
After
  • Coverage strategy

Reimbursement / market access execution

Submission
  • Value dossier
After
  • Coverage

Marketing

Concept
  • Positioning
Submission
  • Launch claims
After
  • Commercial launch

Who this is for

Medical device companies with a defined clinical evidence or Medical Affairs need.

Where we work

  • A founder who needs to know who belongs in the first clinical or regulatory conversation.
  • A CMO or CEO whose clinical plan and claims are not aligned.
  • A medical device program approaching IDE, pivotal, 510(k), or PMA.
  • A company that needs treating physicians prepared with evidence before commercial launch.
  • A feasibility or PMCF study that has stalled.

Where a partner leads

  • Large multicenter studies are run by a trial vendor. We still work on the sponsor side. Small studies we can run.
  • Regulatory representation stays with the company’s regulatory lead. We work alongside, including through exclusive partners.
  • Non-dilutive grants, written by Regenesis Scientific Strategy. Commercial branding and equity fundraising sit with other advisors.
  • Pharmaceutical Clinical or Medical Affairs, and prototype or product-design work, sit outside this practice.

Contact

If you need Clinical and Medical Affairs strategy, get in touch.

A 15- to 30-minute call is enough to see whether we are a fit.

Contact us